Longeveron Q3 net loss $17.3M; cash runs late Q1 2026; BLA for HLHS delayed to 2027

Longeveron Inc.

2025-Q3 EPS reported -$1.07 vs consensus -$0.26 ▼ miss (-311.4%)

Net loss increased 45% to $17.3M for nine months ended Sept 30, 2025 vs $11.9M in prior year.
Revenue fell 53% to $0.8M; cash and equivalents $9.2M, funding expected only into late Q1 2026.
Top-line results from pivotal HLHS Phase 2b trial ELPIS II expected Q3 2026, but BLA submission now anticipated in 2027.
Completed public offering in Aug 2025 raising ~$5.0M; ATM facility of up to $10.7M available.
Leadership: Than Powell appointed Interim CEO; Dr. Joshua Hare named Executive Chairman; Dr. George Paletta elected to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.